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Abstract
Background—Accurate measurement of total cholesterol (TC) is important for cardiovascular 
disease risk management. The US Centers for Disease Control and Prevention (CDC) and 
Cholesterol Reference Method Laboratory Network (CRMLN) perform Abell–Levy–Brodie–
Kendall (AK) reference measurement procedure (RMP) for TC as a secondary reference method, 
and implement Certification Protocol for Manufacturers. Japanese CRMLN laboratory at Osaka 
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performed the AK RMP for 22 years, and conducted TC certification for reagent/calibrator/
instrument systems of six Japanese manufacturers every 2 years for 16 years. Osaka TC 
performance was examined and compared to CDC’s reference values.
Methods—AK RMP involved sample hydrolysis, cholesterol extraction, and determination of 
cholesterol levels by spectrophotometry. The Certification Protocol for Manufacturers includes 
comparison with AK RMP using at least 40 fresh specimens. Demonstration of average bias ≤3% 
and total coefficient of variation ≤3% qualified an analytical system for certification.
Results—In the AK RMP used in the Osaka CRMLN laboratory, the regression equation for 
measuring TC was y (Osaka) = 1.000x (CDC) + 0.032 (n = 619, R2 = 1.000). Six Japanese 
manufacturers had allowable performance for certification.
Conclusions—The AK RMP for TC measurement was accurate, precise, and stable for 22 
years. Six Japanese manufacturers were certified for 16 years.
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1. Introduction
The association between elevated total cholesterol (TC), due to increased low-density 
lipoprotein cholesterol concentrations, and the risk of premature coronary heart disease 
(CHD) has been well documented [1–3]. CHD is the major cause of death in developed 
countries; accurate and reproducible TC measurements are of particular importance for 
correctly and consistently classifying individuals who are at increased risk for this disease, 
as is outlined in the clinical guidelines for the diagnosis, treatment, monitoring, and 
prevention of dyslipidema [4–7].
In 1988, the US Laboratory Standardization Panel [8,9] recommended that cholesterol 
measurements be standardized so that values are traceable to the US Centers for Disease 
Control and Prevention (CDC) reference measurement procedure (RMP) for cholesterol, 
which is a modification of Abell–Levy–Brodie–Kendall (AK) method [10,11]. As a result 
cholesterol tests performed in patient care as well as in clinical studies used to define clinical 
decision levels are standardized to the same AK RMP. This enabled the correct 
interpretation of cholesterol values and efficient implementation of clinical guidelines and 
public health efforts.
The AK RMP is linked to the National Institute of Standards and Technology (NIST) 
method for total serum cholesterol, which involves gas chromatography-isotope dilution 
mass spectrometry (GC-IDMS) [12–15]. The GC-IDMS RMP has higher specificity and 
selectivity than the AK RMP. Thus, results obtained with this method are not 
interchangeable with results from the AK RMP [10,14]. Because AK RMP-based clinical 
decision levels are currently being used in patient care, CDC continues to operate the AK 
RMP and standardizes clinical tests to this method. At the same time, it established a GC-
IDMS RMP [14] to meet the increasing need for more specific and selective clinical 
measurements.
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Epidemiological and large-scale clinical studies have been performed in Japan to investigate 
the risk of cardiovascular disease (CVD) using lipid measurements similar to studies 
conducted in Europe and the United States. The limitations of lipid measurement in Japan 
have historically been the comparability and accuracy of the assayed results. To overcome 
this limitation and to achieve traceable, accurate, and stable lipid measurements over time, 
an epidemiological study group at Osaka Medical Center has participated in the World 
Health Organization (WHO)-CDC Cooperative Cholesterol-Triglyceride Standardization 
Program since April 1975 [15–17]. The standardization of TC measurement at Osaka was 
achieved through the CDC-NHLBI Lipid Standardization Program in the 1970s and 1980s 
using Zak assays [18,19] and enzymatic methods [20,21], which are routinely used to 
analyze cholesterol levels in clinical laboratories in Japan. In 1991, the AK RMP for 
cholesterol was introduced to the epidemiological laboratory at Osaka, and it was 
standardized through the Cholesterol Reference Method Laboratory Network (CRMLN) 
from July 1992 to July 2014. TC certification has been performed by the CDC and CRMLN 
for reagent manufacturers using the Total Cholesterol Certification Protocol for 
Manufacturers [22]. For clinical laboratories, TC certification has been performed using the 
Certification Protocol for Clinical Laboratories [23]. As a result, most Japanese 
manufacturers and many clinical laboratories standardized TC measurements to provide 
traceability to the CDC’s AK RMP. In 2002, the Osaka laboratory established a GC-IDMS 
method similar to CDC’s RMP [24]. The AK RMP and GC-IDMS method have both been 
used continuously and simultaneously through regular CRMLN surveillance under the same 
measurement conditions since July 2012 to the present.
In this study, we present the accuracy and imprecision of the AK RMP obtained at Osaka 
during the course of 22 years. Moreover, we outline an evaluation of the accuracy, precision, 
and total error of reagent/ calibrator/instrument systems of 6 Japanese reagent manufacturers 
that participated in the TC certification program for manufacturers [22] every 2 years for 16 
years.
2. Materials and methods
2.1. Materials
In the CRMLN survey, all standardization pools for TC were created using sera that were 
prepared according to the Clinical and Laboratory Standards Institute Document C37-A 
[25], which defines blood collection, clotting and processing conditions. This suggests that 
no preservatives or additives were added nor was the material lyophilized. CRMLN survey 
pools include round robin samples that were provided from a participating CRMLN 
laboratory, and which included native specimens from patients and 12.1% (75 of 619 runs) 
of all samples. All survey pools were blinded to the CRMLN laboratories. Samples were 
shipped frozen from the CDC, and stored at −70 °C for subsequent analysis.
In the TC Certification Protocol for Manufacturers [22], participating manufacturers 
collected 40 or more fresh specimens from individual fasting donors. The cholesterol 
concentration of these specimens were distributed over a clinically meaningful range, as 
close as possible to the following target distribution: 20% of samples from 120 mg/dL to 
180 mg/dL, 30% of samples from 181 mg/dL to 220 mg/dL, 30% of samples from 221 
Nakamura et al. Page 3
Clin Chim Acta. Author manuscript; available in PMC 2015 September 23.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
mg/dL to 260 mg/dL, and 20% of samples from 261 mg/dL to 400 mg/dL. The minimum 
amount of serum needed per sample for the AK RMP analysis is 1.5 mL. Manufacturers 
analyzed the specimens using their reagent/calibrator/instrument system over 20 runs, with 2 
samples per run. To estimate imprecision, manufacturers should provide quality control 
(QC) single data obtained from 20 separate runs. The recommended concentration range for 
the QC material is 200 mg/dL to 240 mg/dL.
In the Certification Protocol for Clinical Laboratories [23], clinical laboratories analyzed 
two fresh samples in each of the three concentration regions; namely region 1: 100 mg/dL 
and 200 mg/dL, region 2: 200 mg/dL and 240 mg/dL and region 3: >240 mg/dL. The 
samples were assayed using the AK RMP at Osaka.
TC measurements were conducted at the Osaka Medical Center for Cancer and 
Cardiovascular Diseases between July 1997 and June 2001, at the Osaka Medical Center for 
Health Science and Promotion between July 2001 and March 2012, and at the National 
Cerebral and Cardiovascular Center at Osaka continuously since April 2012 (all laboratories 
are referred to as the Osaka laboratory).
2.2. Methods
2.2.1. AK RMP for TC at the Osaka CRMLN laboratory
The AK RMP for TC measurement is a modification of the extraction procedure by Abell et 
al. [10] and the original method was improved at the CDC laboratory [11]. We used a 
Digifiex (ICN, Biomedicals, Inc.) automatic pipettor for aspirating and dispensing standard 
solution, sample, and reagent. Current RMP consists of saponification of a 0.250 mL serum 
sample with alcoholic potassium hydroxide at 50 °C for 1 h, extraction for 20 min with 
hexane using a mechanical shaker in a horizontal position, evaporation of an aliquot of 
extract connected with a vacuum oven, and color development with Liebermann–Burchard 
reagent (mixed reagent of acetic anhydride, glacial acetic acid, and concentrated sulfuric 
acid) at 620 nm using a spectrophotometer (Beckman DU600 and DU800). The AK RMP is 
calibrated using the NIST Standard Reference Material (SRM) of pure unlabeled cholesterol 
(SRM 911c). The working standard solutions of cholesterol in alcohol consist of 25.0, 50.0, 
100.0, 200.0, 300.0, and 400.0 mg/dL concentrations.
2.2.2. TC performance criteria applied to the CRMLN laboratory using AK RMP
TC performance criteria applied to the CRMLN lipid reference laboratory are summarized 
in Table 1. Precision was evaluated in terms of co-efficient of variation (CV, %), and 
accuracy (%bias versus CDC reference value) was evaluated in terms of deviation (%) from 
the CDC reference value.
2.2.3. Statistical criteria of TC certification for manufacturers
Statistical criteria of TC certification for manufacturers are summarized in Table 2A. As a 
reference, statistical criteria of TC certification for clinical laboratories are summarized in 
Table 2B.
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2.3. Statistical analysis
We used the protocol of NCCLS guideline EP9-A from the Clinical and Laboratory 
Standards Institute for bias estimation [26] and the STATA12 analysis program for all other 
calculations [27,28].
3. Results
3.1. Regression, accuracy and precision of TC by AK RMP at Osaka laboratory over time
In the AK RMP for TC measurement at Osaka, the CDC pooled sera with 219 different 
concentrations (lots) were analyzed among 619 survey samples with 165 survey runs, in 
which each survey run consisted of 3 to 4 different pools. There was one native sample from 
patients with low TC concentration ranged 27.7 to 83.4 mg/dL in the three to four provided 
pools: these samples were for the purpose of measuring the accuracy and precision of high-
density lipoprotein cholesterol. The TC concentration ranged from 27.7 to 383.7 mg/dL: 
concentrations were analyzed during the course of 22 years between July 1992 and July 
2014.
In the scatter plots of %bias between Osaka (y) and CDC (x), y = 1.000x + 0.032 (n = 619, 
R2 = 1.000). This means that 200 mg/dL at the CDC corresponds to 200.03 mg/dL at Osaka. 
The p-value and 95% confidence interval (CI) for the slope were p < 0.001 and (1.000, 
1.001), respectively. The p-value and 95% CI for the intercept were p = 0.502 and (−0.061, 
0.124), respectively (Table 3).
In the scatter plots of accuracy, %bias vs. CDC at Osaka, y (Osaka) = −0.001 × (CDC 
reference value) + 0.141 (n: 619, R2 = 0.022). The p-value and 95% CI for the slope were p 
< 0.001 and (−0.001, −0.000), respectively. The p-value and 95% CI for the intercept were p 
< 0.001 and (0.086, 0.195), respectively (Table 3). The Osaka laboratory met the acceptable 
accuracy goals within ± 1% compared to the CDC reference values for 99.0% of the samples 
(613 of 619) (Fig. 1., Table 3). The maximum %bias at Osaka AK RMP was +1.2% and the 
minimum was −1.1% among all 619 samples. The %bias between the reference values of the 
CDC and the measurements of the Osaka laboratory at a medical decision point of 200 
mg/dL was only −0.06% at Osaka.
In the scatter plots of precision, CV(%) at Osaka, y (Osaka CV%) = −0.001 × (CDC 
reference value) + 0.321 (n: 619, R2 = 0.093). The p-value and 95% CI for the slope were p 
< 0.001 and (−0.001, −0.001), respectively. The p-value and 95% CI for the intercept were p 
< 0.001 and (0.286, 0.357), respectively (Table 3). The Osaka laboratory met acceptable 
precision goals < 1% at CV for 99.2% of the samples (614 of 619). The maximum CV at the 
Osaka AK RMP was 1.6% (Fig. 2.).
3.2. Accuracy, precision and total error of Japanese manufacturers conducted by the TC 
Certification Protocol for Manufacturers
Six reagent manufacturers in Japan were evaluated between 1996 and 2012 eight times 
according to the TC Certification Protocol for Manufacturers [22], with regard to their 
analytical systems consisting of a reagent/calibrator/instrument. Their accuracy (mean %bias 
versus reference value by AK RMP), precision (among-run CV), and total error (absolute 
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mean %bias + 1.96 among-run CV) are presented in Table 4A, Table 4B, and Table 4C, 
respectively.
3.3. %Bias plots of TC by Osaka AK RMP at each run over time
Fig. 3 shows the %bias compared to the CDC reference value plots of the Osaka AK RMP at 
each run from a total of 165 runs for 22 years. The minimum value of the %bias was −1.1%, 
whereas the maximum value was 1.2%. The x-axis indicates the survey run number every 20 
runs, and the y-axis indicates the %bias versus CDC reference value of the Osaka AK RMP. 
The acceptable criterion for the accuracy of TC was within ± 1.0% compared to the 
reference value of CDC. Each survey run consisted of three to four CDC pools, including 
round robin samples provided from the CRMLN laboratory for TC analysis.
4. Discussion
The CRMLN maintains robust reference measurement systems with high quality reference 
materials, measurement procedures, and continuous monitoring. Established protocols and 
guidelines within CDC’s CRMLN certification program allows manufacturers to perform 
measurement comparisons between the test method and the reference method to assess 
performance accuracy and imprecision. As shown in earlier reports, CRMLN successfully 
applies this principle to complex analytes such as HDL- and LDL-cholesterol as well as to 
analytes such as total cholesterol. Reliable data allows for consistent patient monitoring, 
treatment management, and improved worldwide public health efforts for CVD.
The AK RMP as operated at the CDC Laboratory and the Osaka laboratory is highly 
accurate and reliable for over 20 years. Measurement results obtained by both laboratories 
show excellent agreement, precision and stability. This ensures assay manufacturers 
calibrated by the Osaka CRMLN laboratory can produce measurement results that are highly 
accurate and comparable over time.
The main purpose of the CRMLN laboratories is to work with manufacturers to certify the 
accuracy and precision of cholesterol measurements of reagent/calibrator/instrument 
systems used in clinical laboratories [29]. This is in agreement with the US Laboratory 
Standardization Panel, which suggests that standardization is most effectively achieved 
through the manufacturers of analytical instruments and reagents [8,9]. Between 1996 and 
2012, six reagent manufacturers in Japan were certified eight times with regard to their 
analytical systems consisting reagent/calibrator/instrument [22]. Standardization of 2,122 
Japanese clinical laboratories has been performed by the Certification Protocol for Clinical 
Laboratories [23] between 1993 and 2014, and 98.2% of these participants met the 
certification criteria, which were derived from clinical needs. This high pass rate with 
clinical laboratories suggests that calibration of assay manufacturers by CRMLN 
laboratories is highly successful and effective. Lipid standardization activities have 
improved the accuracy of TC measurements [30]. All manufacturers and clinical 
laboratories with current certification are listed on CDC’s-CRMLN web site (http://
www.cdc.gov/labstandards/crmln.html).
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The AK RMP was proposed more than 60 years ago and is considered the secondary 
reference method for analyzing cholesterol. It has been used internationally as a reference 
procedure for measuring cholesterol at CDC, CRMLN laboratories, and in many 
epidemiological research institutes worldwide. Despite its widespread use, the AK method 
has limitations such as complex operations, the requirement of skilled technicians, use of 
hazardous reagents, and interferences related to the measurement of reactive substances 
other than cholesterol. These limitations can be minimized with current GC-IDMS RMPs.
Current clinical and public health decision points are based on measurements standardized 
to the AK RMP. Because results obtained with this RMP are not interchangeable with 
results obtained with GC-IDMS RMPs, and a reliable relationship between both types of 
RMPs has not been established yet. The AK RMP continues to be used to standardize tests 
in patient care and public health. At the same time, CDC together with CRMLN laboratories 
including Osaka laboratory is working to further establish mass spectrometry-based RMPs 
for TC and other lipid and lipoproteins [14,31–33]. Mass spectrometry-based RMPs for TC 
and triglycerides are already part of the CRMLN. This will help the clinical and public 
health communities to generate new data and clinical decision points that are linked to new 
more specific mass spectrometry-based RMPs.
5. Conclusions
We presented the performance of TC measurements using the AK RMP over the past 22 
years and demonstrated the accuracy, precision, and long-term stability of this method. As 
examples of AK RMP application, we presented six reagent manufacturers in Japan that 
successfully certified their reagent/calibrator/instrument systems and participated in the TC 
Certification Protocol for Manufacturers for 16 years. The clinical laboratories in Japan 
demonstrated high achievement rates for TC certification. This accomplishment is one 
example on how CRMLN is improving clinical testing of cholesterol and other blood lipids 
not only in Japan but worldwide. These data as well as data shown in previous reports 
demonstrate that the same standardization principles can be applied to analytes such as TC 
as well as highly complex analytes such as HDL- and LDL-cholesterol.
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Fig. 1. 
Accuracy: %Bias plots of Osaka TC by AK RMP. Y-axis indicates the %bias vs. CDC 
reference value of Osaka TC by AK RMP and x-axis indicates CDC reference value by AK 
RMP (mg/dL). CDC: the US Centers for Disease Control and Prevention. AK RMP: Abell–
Kendall reference measurement procedure. TC: total cholesterol.
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Fig. 2. 
Precision: coefficient of variation plots of Osaka TC by AK RMP. Y-axis indicates co-
efficient of variation (CV, %) of Osaka TC by AK RMP and x-axis indicates CDC reference 
value by AK RMP (mg/dL). CDC: the US Centers for Disease Control and Prevention. AK 
RMP: Abell–Kendall reference measurement procedure. TC: total cholesterol.
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Fig. 3. 
%Bias plots of Osaka TC by AK RMP at each run over time. Y-axis indicates Osaka %bias 
vs. CDC reference value and x-axis indicates each survey run from total 165 runs (July 1992 
- July 2014). CDC: The US Centers for Disease Control and Prevention. AK RMP: Abell–
Kendall reference measurement procedure. TC: total cholesterol.
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Table 1
TC performance criteria applied to CRMLN lipid reference laboratory using AK RMP.
Lipid Precision criterion Accuracy criterion
TC Coefficient of variation ≤ 1% Bias (deviation from CDC reference value) ± 1%
CRMLN: Cholesterol Reference Method Laboratory Network. AK RMP: Abell–Levy–Brodie–Kendall Reference Measurement Procedure. TC: 
total cholesterol.
CDC: Centers for Disease Control and Prevention.
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Table 2A
Statistical criteria of TC certification for manufacturer.
Parameter Criterion
r2 >0.975
Bias at 200 mg/dl ≤3%
Bias at 240 mg/dl ≤3%
Average % bias ≤3%
Average absolute % bias ≤3%
Among-run CV ≤3%
Z-test of bias Not significant at α = 5%
Within-method outliers 1 allowed
Between-method outliers None allowed, but may eliminate one sample
Clin Chim Acta. Author manuscript; available in PMC 2015 September 23.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Nakamura et al. Page 15
Table 2B
Statistical criteria of TC certification for clinical laboratory.
Parameter Criterion
r2 >0.975
Bias at 200 mg/dl ≤3%
Bias at 240 mg/dl ≤3%
Average % bias ≤3%
Average absolute % bias ≤3%
Among-run CV ≤3%
t-test of bias Not significant at α = 5%
Within-method outliers 1 allowed
Between-method outliers None allowed, but may eliminate one sample
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